Elevance Health (ELV) Stock Forecast, Price Target & Predictions
ELV Stock Forecast
Elevance Health stock forecast is as follows: an average price target of $556.91 (represents a 1.10% upside from ELV’s last price of $550.84) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
ELV Price Target
The average price target for Elevance Health (ELV) is $556.91 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $649.00 to $335.00. This represents a potential 1.10% upside from ELV's last price of $550.84.
ELV Analyst Ratings
According to 11 Wall Street analysts, Elevance Health's rating consensus is 'Buy'. The analyst rating breakdown for ELV stock is 0 'Strong Buy' (0.00%), 10 'Buy' (90.91%), 1 'Hold' (9.09%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Elevance Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 18, 2024 | Ben Hendrix | RBC Capital | $585.00 | $502.06 | 16.52% | 6.20% |
| Jul 15, 2024 | David MacDonald | Truist Financial | $620.00 | $535.54 | 15.77% | 12.56% |
| Jun 24, 2024 | Erin Wright | Morgan Stanley | $643.00 | $534.42 | 20.32% | 16.73% |
| May 29, 2024 | Michael Ha | Robert W. Baird | $649.00 | $505.52 | 28.38% | 17.82% |
| Apr 19, 2024 | Ben Hendrix | RBC Capital | $575.00 | $525.19 | 9.48% | 4.39% |
| Apr 19, 2024 | AJ Rice | UBS | $605.00 | $525.19 | 15.20% | 9.83% |
| Apr 19, 2024 | Stephen Baxter | Wells Fargo | $600.00 | $525.19 | 14.24% | 8.92% |
| Apr 19, 2024 | David Windley | Jefferies | $604.00 | $525.19 | 15.01% | 9.65% |
| Apr 19, 2024 | Andrew Mok | Barclays | $621.00 | $525.19 | 18.24% | 12.74% |
| Nov 10, 2022 | - | Mizuho Securities | $575.00 | $521.88 | 10.18% | 4.39% |
The latest Elevance Health stock forecast, released on Jul 18, 2024 by Ben Hendrix from RBC Capital, set a price target of $585.00, which represents a 16.52% increase from the stock price at the time of the forecast ($502.06), and a 6.20% increase from ELV last price ($550.84).
Elevance Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 9 |
| Avg Price Target | - | $616.00 | $611.33 |
| Last Closing Price | $550.84 | $550.84 | $550.84 |
| Upside/Downside | -100.00% | 11.83% | 10.98% |
In the current month, the average price target of Elevance Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Elevance Health's last price of $550.84. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 19, 2024 | Stephens | Underperform | Underperform | Hold |
| Aug 19, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jul 19, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 18, 2024 | Barclays | Overweight | Overweight | Hold |
| Jul 18, 2024 | Bank of America Securities | Buy | Neutral | Downgrade |
| Jul 18, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 15, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jun 24, 2024 | UBS | Underperform | Underperform | Hold |
| Jun 24, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jun 11, 2024 | Stephens | Overweight | Overweight | Hold |
Elevance Health's last stock rating was published by Stephens on Aug 19, 2024. The company gave ELV a "Underperform" rating, the same as its previous rate.
Elevance Health Financial Forecast
Elevance Health Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $42.65B | $42.85B | $43.67B | $42.17B | $39.93B | $39.94B | - | $38.09B | $36.58B | $35.82B | $33.85B | $32.38B | $31.82B | $31.16B | $29.26B | $29.62B | $27.41B | $26.67B |
| Avg Forecast | $49.74B | $49.23B | $49.34B | $47.95B | $47.08B | $46.58B | $46.17B | $44.65B | $43.88B | $43.43B | $42.99B | $42.49B | $42.19B | $42.76B | $41.64B | $40.92B | $39.77B | $39.29B | $37.91B | $37.39B | $36.50B | $35.35B | $33.13B | $32.97B | $30.90B | $29.86B | $29.39B | $28.69B | $27.07B | $25.89B |
| High Forecast | $51.20B | $50.67B | $50.79B | $49.36B | $48.46B | $47.95B | $47.53B | $45.96B | $45.17B | $44.39B | $44.25B | $43.74B | $42.82B | $44.02B | $42.86B | $42.12B | $40.94B | $40.45B | $37.91B | $37.99B | $37.08B | $35.90B | $33.65B | $33.49B | $31.39B | $30.33B | $29.85B | $29.14B | $27.49B | $26.30B |
| Low Forecast | $47.26B | $46.77B | $46.88B | $45.56B | $44.74B | $44.26B | $43.87B | $42.43B | $41.70B | $41.33B | $40.85B | $40.38B | $41.13B | $40.63B | $39.56B | $38.88B | $37.79B | $37.34B | $37.91B | $36.97B | $36.09B | $34.94B | $32.75B | $32.60B | $30.55B | $29.52B | $29.05B | $28.36B | $26.76B | $25.60B |
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.00% | 1.05% | 1.03% | 1.00% | 1.02% | - | 1.02% | 1.00% | 1.01% | 1.02% | 0.98% | 1.03% | 1.04% | 1.00% | 1.03% | 1.01% | 1.03% |
Elevance Health's average Quarter revenue forecast for Mar 24 based on 6 analysts is $42.49B, with a low forecast of $40.38B, and a high forecast of $43.74B. ELV's average Quarter revenue forecast represents a -0.36% decrease compared to the company's last Quarter revenue of $42.65B (Dec 23).
Elevance Health EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $449.00M | $32.73B | $34.53B | $3.33B | $1.84B | $2.81B | - | $2.90B | $1.97B | $2.56B | $2.86B | $2.65B | $1.09B | $895.00M | $3.64B | $2.55B | $1.53B | $1.98B |
| Avg Forecast | $2.65B | $2.62B | $2.62B | $2.55B | $2.50B | $2.48B | $2.46B | $2.38B | $2.33B | $2.31B | $2.29B | $3.31B | $2.24B | $2.27B | $2.21B | $3.01B | $2.12B | $2.63B | $2.02B | $2.73B | $1.96B | $2.39B | $2.55B | $2.44B | $1.08B | $884.22M | $3.50B | $2.55B | $1.53B | $1.95B |
| High Forecast | $2.72B | $2.70B | $2.70B | $2.63B | $2.58B | $2.55B | $2.53B | $2.45B | $2.40B | $2.36B | $2.35B | $3.97B | $2.28B | $2.34B | $2.28B | $3.61B | $2.18B | $3.15B | $2.02B | $3.28B | $2.35B | $2.86B | $3.06B | $2.93B | $1.30B | $1.06B | $4.21B | $3.06B | $1.84B | $2.35B |
| Low Forecast | $2.51B | $2.49B | $2.49B | $2.42B | $2.38B | $2.35B | $2.33B | $2.26B | $2.22B | $2.20B | $2.17B | $2.64B | $2.19B | $2.16B | $2.10B | $2.40B | $2.01B | $2.10B | $2.02B | $2.19B | $1.57B | $1.91B | $2.04B | $1.96B | $866.67M | $707.37M | $2.80B | $2.04B | $1.23B | $1.56B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.20% | 14.39% | 15.59% | 1.11% | 0.87% | 1.07% | - | 1.06% | 1.01% | 1.07% | 1.12% | 1.08% | 1.01% | 1.01% | 1.04% | 1.00% | 1.00% | 1.01% |
6 analysts predict ELV's average Quarter EBITDA for Mar 24 to be $3.31B, with a high of $3.97B and a low of $2.64B. This is 636.21% upper than Elevance Health's previous annual EBITDA (Dec 23) of $449.00M.
Elevance Health Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $856.00M | $1.30B | $1.86B | $1.99B | $949.00M | $1.62B | - | $1.80B | $1.13B | $1.51B | $1.79B | $1.67B | $551.00M | $222.00M | $2.28B | $1.52B | $934.00M | $1.18B |
| Avg Forecast | $2.02B | $2.90B | $3.02B | $2.96B | $1.75B | $2.57B | $2.66B | $2.75B | $1.58B | $2.26B | $2.33B | $2.06B | $1.31B | $1.97B | $2.05B | $1.87B | $1.21B | $1.55B | $1.81B | $1.70B | $1.13B | $1.41B | $1.60B | $1.54B | $546.63M | $219.33M | $2.19B | $1.52B | $934.00M | $1.17B |
| High Forecast | $2.09B | $3.01B | $3.14B | $3.08B | $1.81B | $2.66B | $2.76B | $2.86B | $1.64B | $2.38B | $2.42B | $2.47B | $1.32B | $2.05B | $2.13B | $2.25B | $1.26B | $1.86B | $1.81B | $2.04B | $1.36B | $1.69B | $1.92B | $1.84B | $655.95M | $263.19M | $2.63B | $1.83B | $1.12B | $1.40B |
| Low Forecast | $1.89B | $2.71B | $2.83B | $2.77B | $1.63B | $2.40B | $2.49B | $2.57B | $1.48B | $2.14B | $2.18B | $1.65B | $1.29B | $1.85B | $1.92B | $1.50B | $1.13B | $1.24B | $1.81B | $1.36B | $904.26M | $1.13B | $1.28B | $1.23B | $437.30M | $175.46M | $1.76B | $1.22B | $747.20M | $936.58M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.66% | 0.66% | 0.91% | 1.06% | 0.78% | 1.04% | - | 1.06% | 1.00% | 1.07% | 1.12% | 1.08% | 1.01% | 1.01% | 1.04% | 1.00% | 1.00% | 1.01% |
Elevance Health's average Quarter net income forecast for Mar 24 is $2.06B, with a range of $1.65B to $2.47B. ELV's average Quarter net income forecast represents a 140.77% increase compared to the company's last Quarter net income of $856.00M (Dec 23).
Elevance Health SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.80B | $4.56B | $4.51B | - | $4.34B | $4.22B | $3.95B | $3.82B | $3.92B | $4.32B | $5.30B | $4.05B | $3.78B | $3.50B | $3.42B |
| Avg Forecast | $7.08B | $7.01B | $7.02B | $6.83B | $6.70B | $6.63B | $6.57B | $6.36B | $6.25B | $6.18B | $6.12B | $4.96B | $6.01B | $6.09B | $5.93B | $4.51B | $5.66B | $4.05B | $5.40B | $4.10B | $4.20B | $3.69B | $3.41B | $3.62B | $4.28B | $5.24B | $3.90B | $3.78B | $3.50B | $3.38B |
| High Forecast | $7.29B | $7.21B | $7.23B | $7.03B | $6.90B | $6.83B | $6.77B | $6.54B | $6.43B | $6.32B | $6.30B | $5.95B | $6.10B | $6.27B | $6.10B | $5.41B | $5.83B | $4.87B | $5.40B | $4.92B | $5.04B | $4.42B | $4.09B | $4.35B | $5.14B | $6.29B | $4.68B | $4.54B | $4.20B | $4.06B |
| Low Forecast | $6.73B | $6.66B | $6.68B | $6.49B | $6.37B | $6.30B | $6.25B | $6.04B | $5.94B | $5.88B | $5.82B | $3.97B | $5.86B | $5.79B | $5.63B | $3.60B | $5.38B | $3.24B | $5.40B | $3.28B | $3.36B | $2.95B | $2.72B | $2.90B | $3.43B | $4.19B | $3.12B | $3.02B | $2.80B | $2.71B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 0.81% | 1.11% | - | 1.06% | 1.01% | 1.07% | 1.12% | 1.08% | 1.01% | 1.01% | 1.04% | 1.00% | 1.00% | 1.01% |
Elevance Health's average Quarter SG&A projection for Jun 23 is $5.93B, based on 9 Wall Street analysts, with a range of $5.63B to $6.10B. The forecast indicates a 23.50% rise compared to ELV last annual SG&A of $4.80B (Mar 23).
Elevance Health EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 13 | 16 | 8 | 6 | 12 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 6 | 5 | 4 | 4 | 7 | 4 | 4 | 3 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $3.63 | $5.48 | $7.83 | $8.44 | $3.99 | $6.75 | - | $7.41 | $4.65 | $6.20 | $7.33 | $6.80 | $2.25 | $0.88 | $9.02 | $6.03 | $3.69 | $4.64 |
| Avg Forecast | $8.64 | $12.42 | $12.94 | $12.70 | $7.48 | $11.00 | $11.39 | $11.79 | $6.79 | $9.70 | $10.00 | $10.52 | $5.60 | $8.46 | $8.78 | $9.29 | $5.19 | $7.15 | $7.75 | $7.81 | $5.11 | $6.37 | $6.34 | $6.41 | $2.53 | $4.12 | $8.74 | $6.47 | $3.88 | $4.82 |
| High Forecast | $8.97 | $12.89 | $13.44 | $13.19 | $7.76 | $11.42 | $11.82 | $12.24 | $7.05 | $10.18 | $10.38 | $10.92 | $5.67 | $8.78 | $9.12 | $9.64 | $5.39 | $7.43 | $7.75 | $7.97 | $5.22 | $6.50 | $6.47 | $6.55 | $2.58 | $4.21 | $8.92 | $6.61 | $3.96 | $4.92 |
| Low Forecast | $8.08 | $11.61 | $12.11 | $11.88 | $6.99 | $10.28 | $10.65 | $11.03 | $6.35 | $9.16 | $9.35 | $9.84 | $5.53 | $7.91 | $8.22 | $8.69 | $4.85 | $6.69 | $7.75 | $7.69 | $5.04 | $6.28 | $6.24 | $6.32 | $2.49 | $4.06 | $8.61 | $6.38 | $3.83 | $4.75 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.65% | 0.89% | 0.91% | 0.77% | 0.94% | - | 0.95% | 0.91% | 0.97% | 1.16% | 1.06% | 0.89% | 0.21% | 1.03% | 0.93% | 0.95% | 0.96% |
According to 6 Wall Street analysts, Elevance Health's projected average Quarter EPS for Mar 24 is $10.52, with a low estimate of $9.84 and a high estimate of $10.92. This represents a 189.79% increase compared to ELV previous annual EPS of $3.63 (Dec 23).
Elevance Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CVS | CVS Health | $57.98 | $103.77 | 78.98% | Hold |
| HUM | Humana | $321.56 | $500.84 | 55.75% | Hold |
| CNC | Centene | $75.35 | $92.60 | 22.89% | Buy |
| ELV | Elevance Health | $550.84 | $556.91 | 1.10% | Buy |
| MOH | Molina Healthcare | $358.20 | $358.63 | 0.12% | Hold |
| UNH | UnitedHealth Group | $594.32 | $569.20 | -4.23% | Buy |
| CI | Cigna | $364.72 | $318.74 | -12.61% | Buy |
| ALHC | Alignment Healthcare | $11.89 | $9.50 | -20.10% | Buy |
ELV Forecast FAQ
Is Elevance Health a good buy?
Yes, according to 11 Wall Street analysts, Elevance Health (ELV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 10 'Buy' recommendations, accounting for 90.91% of ELV's total ratings.
What is ELV's price target?
Elevance Health (ELV) average price target is $556.91 with a range of $335 to $649, implying a 1.10% from its last price of $550.84. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Elevance Health stock go up soon?
According to Wall Street analysts' prediction for ELV stock, the company can go up by 1.10% (from the last price of $550.84 to the average price target of $556.91), up by 17.82% based on the highest stock price target, and down by -39.18% based on the lowest stock price target.
Can Elevance Health stock reach $800?
ELV's average twelve months analyst stock price target of $556.91 does not support the claim that Elevance Health can reach $800 in the near future.
What are Elevance Health's analysts' financial forecasts?
Elevance Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $184.49B (high $189.91B, low $175.3B), average EBITDA is $9.81B (high $10.1B, low $9.33B), average net income is $9.72B (high $10.09B, low $9.09B), average SG&A $26.27B (high $27.04B, low $24.96B), and average EPS is $41.65 (high $43.24, low $38.96). ELV's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $196.25B (high $202.02B, low $186.48B), average EBITDA is $10.44B (high $10.75B, low $9.92B), average net income is $10.9B (high $11.32B, low $10.2B), average SG&A $27.94B (high $28.76B, low $26.55B), and average EPS is $46.7 (high $48.49, low $43.68).
Did the ELV's actual financial results beat the analysts' financial forecasts?
Based on Elevance Health's last annual report (Dec 2023), the company's revenue was $171.34B, beating the average analysts forecast of $167.5B by 2.29%. Apple's EBITDA was $1.74B, missing the average prediction of $9.74B by -82.12%. The company's net income was $5.99B, missing the average estimation of $7.2B by -16.90%. Apple's SG&A was $0, missing the average forecast of $22.53B by -100.00%. Lastly, the company's EPS was $25.22, missing the average prediction of $32.13 by -21.51%. In terms of the last quarterly report (Dec 2023), Elevance Health's revenue was $42.65B, beating the average analysts' forecast of $42.19B by 1.09%. The company's EBITDA was $449M, missing the average prediction of $2.24B by -79.99%. Elevance Health's net income was $856M, missing the average estimation of $1.31B by -34.48%. The company's SG&A was $0, missing the average forecast of $6.01B by -100.00%. Lastly, the company's EPS was $3.63, missing the average prediction of $5.6 by -35.15%